Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Ad hoc announcement pursuant to Article 53 of the SIX listing rulesKuros Biosciences reports 51% year-over-year increase in sales in the first ...

Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutionsSchlieren (Zurich), Switzerland, April 15, 2026 – Kuros Biosciences (“Kuros” ...

Kuros Biosciences AG: Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 Financial Highlights Total ...

Kuros Biosciences AG: Annual General Meeting of Kuros Biosciences approves all resolutions

Annual General Meeting of Kuros Biosciences approves all resolutions Schlieren (Zurich), Switzerland, April 15, 2026 - Kuros Biosciences ("Kuros" or the "Company") a leader in next generation bone ...
Orthopedics This Week

The Biologics Wake-Up Call Nobody Wanted to Give

It’s time to say out loud: osteobiologics has been coasting for a decade. Not failing — coasting.
Barron's

Regencell Bioscience Holdings Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Barron's

TuHURA Biosciences Inc.

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product ...